Search

Author/Creator Kalakonda, N.

1. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019)

Authors:
Kalakonda, N.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.; Casasnovas, O.; Lavee, O.; Maerevoet, M.; Zijlstra, J.; Bakshi, S.; Bouabdallah, R.; Choquet, S.; Gurion, R.; Hill, B.; Jaeger, U.; Sancho, J.; Schuster, M.; Thieblemont, C.; De la Cruz, F.; Egyed, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
62
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL. (12th June 2019)

Authors:
Pettitt, A.; Kalakonda, N.; Cicconi, S.; Murphy, C.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.; Knechtli, C.; Hamblin, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
217
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. CHOP VERSUS GEM‐P IN THE FIRST‐LINE TREATMENT OF T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO‐T TRIAL. (June 2017)

Authors:
Gleeson, M.; Peckitt, C.; To, Y.M.; Edwards, L.; Chau, I.; Johnson, P.; Ardeshna, K.M.; Wotherspoon, A.; Attygalle, A.; Begum, R.; Chua, S.; Zerizer, I.; Hawkes, E.A.; Macheta, M.P.; Collins, G.P.; Radford, J.A.; Forbes, A.; Hart, A.; Montoto, S.; McKay, P.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
75
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (June 2017)

Authors:
Pettitt, A.R.; Kalakonda, N.; Polydoros, F.; Bickerstaff, M.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Jenner, M.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.P.; Knechtli, C.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
88
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. (12th June 2019)

Authors:
Radford, J.; Connors, J.M.; Younes, A.; Gallamini, A.; Ansell, S.M.; Kim, W.S.; Cheong, J.; Flinn, I.; Kalakonda, N.; Kaminski, M.; Pettengell, R.; Onsum, M.; Josephson, N.; Kuroda, S.; Liu, R.; Miao, H.; Gautam, A.; Trepicchio, W.L.; Sureda, A.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
290
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. L‐MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R‐R DLBCL) – A SINGLE‐ARM PHASE II STUDY. (June 2017)

Authors:
Salles, G.; González Barca, E.; Jurczak, W.; Liberati, A.M.; Duell, J.; Nagy, Z.; Papajík, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P.L.; Ambarkhane, S.; Weirather, J.; Maddocks, K.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
51
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA. (12th June 2019)

Authors:
Pettitt, A.R.; Barrington, S.; Kalakonda, N.; Khan, U.T.; Jackson, R.; Carruthers, S.; Oates, M.; Lin, K.; Ardeshna, K.; Eyre, T.; Fox, C.P.; Kennedy, B.; Linton, K.; Malladi, R.; Menne, T.; Okosun, J.; Paneesha, S.; Rule, S.; Johnston, A.; Trotman, J.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
67
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P1187: END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOSTIC FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PERIPHERAL T-CELL LYMPHOMA: RESULTS OF THE UK NCRI PHASE 2 RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY. (23rd June 2022)

Authors:
Gleeson, M.; Arias, C.; Cunningham, D.; Peckitt, C.; Du, Y.; Hujairi, N.; To, Y. M.; Chen, H.-C.; Patel, S.; Chau, I.; Johnson, P.; Ardeshna, K. M.; Wotherspoon, A.; Attygalle, A.; Hawkes, E. A.; Macheta, M. P.; Collins, G. P.; Radford, J.; Forbes, A.; Hart, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1073
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES. (12th June 2019)

Authors:
Till, K.J.; Gallardo Zapata, J.; Marks, T.; Weaver, D.T.; Pachter, J.A.; Abdullah, M.; Kalakonda, N.; Pettitt, A.R.; Slupsky, J.R.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
511
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗